• Konfoong Biotech International

  Participated · Series B · Apr 2020

  Founded in 2011, 江丰生物 focuses on integrated smart pathology solutions including pathology pre-processing equipment, digital slide scanners, pathology AI, pathology information systems, and diagnostic services. The company says its digital pathology products occupy the high-end domestic market and have been deployed in over 2,000 hospitals and multiple regional pathology centers and top-tier hospitals. It claims leadership in domestic digital-pathology market share and was an early recipient of a deep-learning based pathology AI Class II certificate in 2019, with a Class III submission via a green channel underway. 江丰生物 has formed industry partnerships with institutions and vendors such as the Chinese Maternal and Child Health Association, Huawei, Intel and H3C to accelerate deployment. The company reports growing international traction with customers in Europe, Southeast Asia, Russia, Latin America and Australia and plans a large cervical-cancer screening project in Brazil. Management expects domestic and international revenue to reach rough parity within 3–5 years, using overseas markets as a major growth engine. Konfoong Biotech (also known as KFBIO) is a China-based pathology technology developer and cancer diagnostics system provider. The company provides medical devices that scan and process. Konfoong closed a Series B round sized at up to RMB100 million (about $14.1 million) led by Intel Capital. The round included Zhejiang Xinganxian Media Investment, a vehicle of Zhejiang Daily Press, and venture firm Yingxinggu Capital. Intel's parent company had previously supplied Konfoong with artificial-intelligence technology. No other financial metrics or future plans were disclosed in the article.

No current team members are available.